Nonetheless, the assessment of PD-L1 biomarker via immunohistochemistry (IHC), commonly quantified as the combined positive score (CPS) or tumor proportion score (TPS) (6), is both resource-intensive and time-consuming (7). This evidence concerns the gene CD274 and neoplasm.